PDGFRB and neoplasm: Among the four groups of subcutaneous tumor mice constructed with PDGFRβ-overexpressing cells, the tumor growth rate in the Ezetimibe or MK2206 treatment group alone was significantly slower than that in the vehicle control group, and the tumor growth rate in the Ezetimibe combined with MK2206 treatment group was significantly slower than in the other three groups (Fig. 6B).